Natixis Advisors, L.P. Seagen Inc. Transaction History

Natixis Advisors, L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	SELL	$187.64 - $206.25 $1.9 Million - $2.09 Million	-10,149 Reduced 34.29%	19,452 $3.74 Million
Q1 2023 May 11, 2023	BUY	$127.59 - $203.08 $706,210 - $1.12 Million	5,535 Added 23.0%	29,601 $5.99 Million
Q4 2022 Jan 27, 2023	SELL	$117.37 - $139.17 $124,177 - $147,241	-1,058 Reduced 4.21%	24,066 $3.09 Million
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $56,813 - $75,646	420 Added 1.7%	25,124 $3.44 Million
Q2 2022 Aug 12, 2022	SELL	$108.81 - $179.33 $76,819 - $126,606	-706 Reduced 2.78%	24,704 $4.37 Million

Q1 2022 May 12, 2022	BUY	$119.61 - $157.85 $189,701 - $250,350	1,586 Added 6.66%	25,410 $3.66 Million
Q4 2021 Feb 08, 2022	SELL	$142.57 - $190.86 $82,405 - $110,317	-578 Reduced 2.37%	23,824 $3.68 Million
Q3 2021 Nov 15, 2021	BUY	$142.45 - $169.82 $195,868 - $233,502	1,375 Added 5.97%	24,402 $4.14 Million
Q2 2021 Aug 12, 2021	BUY	$135.08 - $161.1 $13,643 - $16,271	101 Added 0.44%	23,027 $3.64 Million
Q1 2021 May 05, 2021	SELL	$137.51 - $190.8 $1.06 Million - $1.48 Million	-7,740 Reduced 25.24%	22,926 $3.18 Million
Q4 2020 Feb 12, 2021	BUY	$164.63 - $211.93 $5.05 Million - $6.5 Million	30,666 New	30,666 $5.37 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

Stay updated on Natixis Advisors, L.P. with notifications on news.